UCB Predicts Briviact Sales Of €450m by 2026; Plans New Partnerships
Executive Summary
UCB says its early to mid-stage pipeline contains 10 promising breakthrough molecules, some of which it aims to partner with other pharma players as part of its open innovation strategy.
You may also be interested in...
Zydus Sets Sight On First US Generic Of UCB’s Briviact
Zydus Cadila has scooped another material ANDA approval from the FDA, with the green light for its generic version of UCB’s Briviact to treat partial-onset seizures.
UCB’s Cimzia Set To Make A Late Entrance At Psoriasis Party
UCB has reported positive data from the final Phase III trial of its anti-TNF product Cimzia in plaque psoriasis, paving the way for approval applications later this year, but the product will have to elbow its way into a competitive market already under the shadow of a biosimilar threat.
UCB's Keppra Follow-On Briviact Gains FDA Nod For Epileptic Seizures
A next-generation version of levetiracetam, brivaracetam could help UCB recapture some revenue it's losing to generic competition for the mature epilepsy drug.